Wordmark and Logo
Logos, monogram, lockups
Primary wordmark in horizontal and stacked lockups. Monogram for square placements. Light, dark, and reversed variants. SVG, PNG (transparent), and PDF inside the press kit ZIP under /logos.
Press Room · Updated Monthly · Quotes and Logos Pre-Cleared
Reporters: everything you need to write about Burna AI accurately.
Burna AI is the safety and data quality platform for oncology drug development, from clinical trials through postmarket surveillance. Fact sheet, boilerplate, founder bios, brand assets, speaking calendar, and a press contact who responds in one business day.
CancerX member, HHS Cancer Moonshot Initiative. FDA Emerging Drug Safety Technology Program application in review. Two patents filed. Twenty-five advisors across five councils. Conservative on numbers; specific on commitments.
Founded2024 · US-HQ
MembershipsCancerX · FDA EDSTP in review
Advisors25 across 5 councils
2024 founded
United States headquartered. Small senior team, distributed internationally.
CancerX member
HHS Cancer Moonshot Initiative. FDA EDSTP application in review. SMART on FHIR certified across major EHRs.
25 advisors · 02 patents
Across five councils. Two patents filed on the cascading constraint pipeline.
01 / Boilerplate
Boilerplate. Lift verbatim.
The paragraphs below are the canonical company descriptions. They are cleared for verbatim use in any article, press release, conference program, podcast intro, or analyst report. No permission required.
The canonical one-liner
Burna AI is the safety and data quality platform for oncology drug development, from clinical trials through postmarket surveillance.
Short boilerplate (45 words)
Burna AI is the safety and data quality platform for oncology drug development, from clinical trials through postmarket surveillance. The platform pairs citation-bound CTCAE coding and grading with multi-drug attribution. Human-in-the-loop, always. CancerX member. FDA Emerging Drug Safety Technology Program application in review.
Long boilerplate (95 words)
Burna AI is the safety and data quality platform for oncology drug development, from clinical trials through postmarket surveillance. The proprietary Burna AI engine is a patented cascading constraint pipeline of twelve specialized agents that produces CTCAE coding, including TERM and CATEGORY, coupled with intelligence to support determination of Severity GRADE, with mandatory citation to source text. Burna serves cancer centers, pharma and biotech sponsors, and contract research organizations through a single platform with regional deployment across the US, UK, EU, APAC, and MENA. Founded in 2024 by Nnenna John. Headquartered in the United States.
02 / At a Glance
Burna AI at a glance.
Two-column fact panel. For more depth or for any number not listed here, email press@burna.ai.
- Founded
- 2024
- Headquarters
- United States
- Legal entity
- Delaware C-corporation
- Team
- Small, senior, distributed internationally
- Founder and CEO
- Nnenna John
- Lead Engineer and Co-Founder
- Paschal Ezeugwu
- Advisors
- 25 across 5 councils (Clinical, Regulatory & Standards, Tech & Product, Commercial, Brand & Adoption)
- Funding stage
- Seed (open as of 2026)
- Patents
- Two filed on the cascading constraint pipeline
- Memberships
- CancerX (HHS Cancer Moonshot Initiative)
- Regulatory
- FDA Emerging Drug Safety Technology Program application in review
- Certifications
- SMART on FHIR certified across major EHRs. 21 CFR Part 11 aligned. HIPAA aligned. GDPR aligned. SOC 2 Type II audit kicked off Q2 2026.
- Accelerator
- Accepted into a top-tier NCI-designated cancer center accelerator program
- Product lines
- CTCAE AI (cancer centers, AMCs, CROs) and Protocol Safe (pharma sponsors)
- Coverage
- 837+ CTCAE criteria (v5.0 and v6.0). 42 oncology regimen profiles.
- Algorithms
- WHO-UMC and Kramer causality attribution, both regulator-recognized by FDA, EMA, PMDA, MHRA
- Governance
- Human-in-the-loop, always
03 / Executive Bios
Quote-ready, print-friendly.
The bios below are pre-cleared for editorial use. Shorter and longer cuts available on request at press@burna.ai.
NJ
Nnenna John, Founder and CEO · Short (60 words)
Nnenna John is the Founder and CEO of Burna AI. She spent six years at Airbnb building infrastructure for 150 million users across 220 countries, and earlier worked on regulated systems at JP Morgan Chase. She founded Burna AI in 2024 and architected the cascading constraint pipeline that produces every Burna grade with its citation and attribution.
NJ
Nnenna John, Founder and CEO · Long (140 words)
Nnenna John is the Founder and CEO of Burna AI, the safety and data quality platform for oncology drug development. She has nineteen-plus years of platform engineering experience, including six years at Airbnb building infrastructure that served 150 million users across 220 countries, and earlier work on regulated financial systems at JP Morgan Chase. She founded Burna AI in 2024 after a personal experience with the gap between what cancer trial safety operations need and what the field’s tools provide. She architected the patented twelve-agent cascading constraint pipeline that produces every Burna suggested grade with its source sentence, CTCAE criterion, and multi-drug attribution path. A domain outsider to clinical trials with an insider’s advisory network, she leads Burna AI with a stated principle of implementation over hype.
PE
Paschal Ezeugwu, Lead Engineer and Co-Founder · Short (45 words)
Paschal Ezeugwu is the Lead Engineer and Co-Founder of Burna AI. He has deep experience in distributed systems, healthcare integrations, and the quiet infrastructure that must never fail. Paschal leads the platform engineering for every Burna deployment, from on-premises hospital networks to regional sovereign clouds.
PE
Paschal Ezeugwu, Lead Engineer and Co-Founder · Long (110 words)
Paschal Ezeugwu is the Lead Engineer and Co-Founder of Burna AI. He leads platform engineering across the full deployment stack: SMART on FHIR integration inside Epic, Oracle Health, and regional EHRs; on-premises hospital network deployments; regional cloud deployments with sovereignty controls in the US, UK, EU, APAC, and MENA; sponsor-tenant architecture for pharma engagements; and the EDC integration layer for Medidata Rave, Veeva Vault EDC, and Oracle Clinical One. His background is in distributed systems, healthcare integration, and the quiet infrastructure that must never fail. Paschal runs the platform-side of every Burna deployment and owns the architecture that keeps patient identifiers inside the institution’s network.
Interview availability for Nnenna John: company strategy, fundraising, product vision, oncology safety market, clinical AI industry perspective, design partnership model, international strategy, women-founded health-tech, Africa-rooted founders in clinical AI. For Paschal Ezeugwu: product architecture, infrastructure, healthcare integration, citation-bound output design, sovereign cloud deployment, 21 CFR Part 11 technical alignment.
04 / Brand Assets
Pre-cleared for editorial use.
The assets below are available for download. High-resolution variants, source files, and any asset not listed here are available on request: press@burna.ai.
Executive Bios
Bios in short and long cuts
Nnenna John and Paschal Ezeugwu bios in short, medium, and long cuts. Pre-cleared for editorial use. Available as DOCX, MD, and PDF inside the press kit ZIP.
Brand Assets
Palette, typography, photography
Brand violet primary, cream and soft cream editorial register. Rethink Sans (editorial and product) and Geist Mono (code, citation IDs, CTCAE codes). Founder headshots, environmental portraits, and product screenshots available on request.
Usage policy. Logos and brand assets may be used in editorial coverage without prior written permission. Commercial use, merchandise, derivative works, or modifications (stretching, recoloring outside the official palette, overlays on non-approved backgrounds) require written permission from press@burna.ai.
05 / Speaking and Conferences
Speaking calendar and recent appearances.
The calendar below is updated monthly. For interview requests tied to a conference appearance, email press@burna.ai with the publication and the angle. Burna coordinates with the speaker’s calendar.
APR
AI in Oncology, Germany · April 24, 2026
Dr. Stefan Gluck presenting on citation-bound architecture and oncology safety operations.
MAY
ESMO Breast Cancer, Berlin · May 8 to 9, 2026
Dr. Stefan Gluck presenting.
JUN
ASCO Annual Meeting, Chicago · May 29 to June 2, 2026
Dr. Stefan Gluck presenting.
2026
Bio-IT World, Boston
Poster target: US 1,200-chart accuracy study at an NCI-designated comprehensive cancer center.
MS
Manuscripts in preparation
JCO Clinical Cancer Informatics submissions in preparation (2026 to 2027). Target manuscripts include the prospective workflow study at a US cancer center and the 1,200-chart retrospective accuracy study. Pre-prints will publish on medRxiv within sixty days of database lock.
MED
Media coverage and analyst reports
The current coverage list is maintained at press@burna.ai. Burna AI declines to publish specific accuracy percentages outside peer-reviewed venues; please request the validation summary if your story requires a quantitative framing.
06 / Speaking Topics
What the team speaks to.
The list below is what Burna AI spokespeople are prepared to discuss on panels, podcasts, and at conferences. For a topic not listed here, email press@burna.ai with the framing.
- The Burna AI engine: a twelve-agent cascading constraint pipeline with two patents filed.
- Citation-bound architecture in clinical AI: the architectural difference between an LLM wrapper and a constraint-pipeline engine.
- The pre-registered validation methodology: paired-grader timing, documentation completeness, attribution agreement, peer-reviewed target venues.
- Per-trial query economics in oncology: the $192K to $710K labor band at industry-standard rates and the share that is structurally closeable.
- Oncology trial safety operations: the coordinator-side reality of running 80 to 200 active oncology trials.
- The risk-reversed pilot model: why a co-authored peer-reviewed manuscript is the procurement asset.
- The 12-pillar implementation playbook: what ships with every Burna AI pilot.
- Sovereign cloud deployment in healthcare AI: how patient identifiers stay inside the institution’s jurisdiction.
- Founder perspective: building infrastructure-class clinical AI as a domain outsider with an insider’s advisory network.
- The CancerX membership and the FDA EDSTP pathway in 2026.
07 / Press Contact
One inbox. One business day.
The press desk coordinates founder interviews, advisor introductions, named advisor quotes, conference panel requests, and on-the-record commentary on company strategy, regulatory developments, and scientific publications.
Press Inquiries
press@burna.ai · general desk
Press inquiries, embargoed news, interview requests, and time-sensitive coverage. First response within one business day during standard cycles. Same-day for breaking news on request; include "Urgent" or "Embargoed" in the subject line.
One business day during standard cycles. Same-day on request.
Founder Direct
nnenna@burna.ai · sensitive only
For sensitive or exclusive coverage, founder profile pieces, or board-level inquiries. Routes directly to Nnenna John, Founder and CEO.
For routine press, route to press@burna.ai first.
08 / Editorial Guidance
Offered to help you file faster.
Reference for accuracy. Lift verbatim or paraphrase. For anything not addressed, email press@burna.ai and Burna will confirm.
NAME
On the company name
"Burna AI" on first reference, "Burna" thereafter. Two words, capital B, capital AI, no hyphen, no period.
CAT
On the product category
"Safety and data quality platform for oncology drug development" or "clinical infrastructure for oncology safety." Not "medical device." Not "diagnostic tool."
ARCH
On the architecture
Use "Twelve specialized agents in a patented cascading constraint pipeline," "citation-bound by design," and "two patents filed." The architecture produces CTCAE coding, including TERM and CATEGORY, coupled with intelligence to support determination of Severity GRADE, with mandatory citation to source text.
ALGO
On the algorithms
Please name them. "WHO-UMC and Kramer causality algorithms." Not "proprietary AI."
ACC
On accuracy
Burna AI declines to publish specific accuracy percentages outside peer-reviewed venues. In external coverage, please use "strong agreement with expert clinicians in ongoing internal testing." Full numbers publish in peer-reviewed papers (target 2026 to 2027).
REG
On regulatory status
"FDA Emerging Drug Safety Technology Program application in review." Not "FDA-approved." Not "FDA-cleared." Not "FDA-aligned."
GOV
On governance
"Human-in-the-loop, always" and "AI suggests, clinicians decide." Not "autonomous." Not "replaces clinicians."
TITLE
On founder title
"Nnenna John, Founder and CEO, Burna AI." Never "Co-Founder." Never "CEO" alone.
ACC
On the cancer center accelerator
"A top-tier NCI-designated cancer center accelerator program." The specific institution is confidential.
DUKE
On Duke Health
Dr. Aman Opneja is Burna AI’s Chief Trials Officer and an advisor in his personal capacity. He is a practicing GI oncologist at Duke Health. Duke Health is not an institutional partner of Burna AI.
VAL
On the US validation engagement
Treat institution naming as sensitive unless the publication has explicit approval. In public copy without approval, use "US validation engagement" or "prospective workflow study at a US cancer center."
09 / Further Reading
Where to read next.
The pages below extend the press kit with audience-specific depth. For anything not covered, the press desk routes.
Email the press desk →- /about →Who we are and what we believe.
- /engine →The cascading constraint pipeline in technical detail.
- /it-and-security →HIPAA, 21 CFR Part 11, GDPR alignment and sovereignty controls.
- /cancer-centers →Audience-specific platform detail for cancer centers.
- /pharma →Audience-specific platform detail for pharma sponsors.
- /investors →Investor brief, comparables, diligence package.
Not on a deadline?
Subscribe to the quarterly safety and data quality briefing. Validation readouts, platform updates, and conference timing only. No tracking beacons, no marketing email cadence.